Table 3.
Baseline characteristics of patients.
| Placebo (n = 5) | THSW (n = 6) | P | |
|---|---|---|---|
| Gender (F/M) | 1/4 | 3/3 | 0.545 |
| Age, year | 55.60 ± 6.47 | 59.83 ± 7.39 | 0.344 |
| BMI, kg/m2 | 25.55 ± 5.26 | 25.49 ± 2.79 | 0.983 |
| SBP, mm Hg | 121.60 ± 16.70 | 132.33 ± 12.36 | 0.251 |
| DBP, mm Hg | 83.60 ± 9.94 | 77.67 ± 8.98 | 0.325 |
| Heart rate, beats/min | 70.40 ± 6.07 | 67.50 ± 7.53 | 0.506 |
| RBC,×1012/L | 4.71 ± 0.15 | 4.65 ± 0.54 | 0.805 |
| HGB, g/L | 140.40 ± 7.57 | 141.33 ± 18.10 | 0.912 |
| WBC,×109/L | 6.06 ± 1.98 | 6.64 ± 1.02 | 0.544 |
| NE, % | 63.60 ± 9.72 | 58.92 ± 9.20 | 0.433 |
| PLT,×109/L | 225.80 ± 43.34 | 219.67 ± 28.40 | 0.784 |
| AST, U/L | 22.38 ± 2.00 | 21.02 ± 5.72 | 0.604 |
| ALT, U/L | 25.60 ± 8.61 | 27.98 ± 19.50 | 0.807 |
| SCr, μmol/L | 75.98 ± 14.73 | 68.33 ± 18.87 | 0.480 |
| BUN, mmol/L | 5.05 ± 0.86 | 5.43 ± 1.01 | 0.524 |
| UA, μmol/L | 338.14 ± 87.40 | 365.48 ± 70.43 | 0.579 |
| TG, mmol/L | 1.97 ± 1.39 | 1.49 ± 0.60 | 0.465 |
| TC, mmol/L | 2.90 ± 1.43 | 4.73 ± 0.64* | 0.020 |
| HDL, mmol/L | 1.30 ± 0.47 | 1.19 ± 0.29 | 0.631 |
| LDL, mmol/L | 1.96 ± 0.49 | 2.96 ± 0.31* | 0.003 |
| Glu, mmol/L | 4.98 ± 0.56 | 5.42 ± 0.44 | 0.180 |
| PT, s | 13.12 ± 0.55 | 12.35 ± 0.83 | 0.112 |
| APTT, s | 37.42 ± 1.72 | 33.55 ± 2.50* | 0.017 |
| FIB, g/L | 2.83 ± 0.34 | 2.80 ± 0.48 | 0.902 |
| TT, s | 16.42 ± 0.66 | 17.58 ± 2.92 | 0.409 |
Values are mean ± SD.
*P < 0.05 vs. the placebo group.
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; RBC, red blood cell; HGB, hemoglobin; WBC, white blood cell; NE, neutrophil; PLT, platelet; AST, aspartate aminotransferase; ALT, alanine aminotransferase; SCr, serum creatinine; BUN, blood urea nitrogen; UA, uric acid; TG, triglyceride; TC, total cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein; Glu, glucose; PT, prothrombin time; APTT, activated partial thromboplastin time; FIB, fibrinogen; TT, thrombin time.